That our WADA develop government legislation to combat the extension of the practice of pharmacists, which considers itself inappropriate or constitutes the practice of medicine, including, but not only, the issue of the interpretation or application of independent practices, without adequate medical supervision and cooperation with the States and specialties concerned, to advance this legislation (Action Directive).  In the keynote address at the 2013 APH annual meeting, Reid Blackwelder, president of the American Academy of Family Physics (AAFP)  called for a “collaborative vision of public health.”  October 1, 2013, Ca Governor Jerry Brown signed Senate Bill 493, which makes a pharmacist a health care provider and gives him the power to provide hormonal contraceptives, nicotine substitutes, vaccines, including travel vaccines, which do not require diagnosis but are recommended by the CDC to order and interpret drug recommendations and laboratory tests to optimize drug therapy.  The bill also included the “Advanced Practice Pharmacist” (APh) classification, defined by the California State State Board of Pharmacy as a licensed pharmacist, which must meet two of the following criteria: Arkansan`s marketing licensing services apply to individual pharmacists, practitioners who are defined as “authorized practitioners to prescribe drugs” and patients. The specific disease stipulates that pharmacists administer, with indicated medications that the pharmacist can use are necessary. Pharmacists are required to document their interventions for discussion with the collaborative practitioner and must keep these records for at least 2 years after the date of registration.  Alaska`s CPAs may include several pharmacists and practitioners (for example. B a pharmacist who takes a CPA with a group of staff physicians, several pharmacists who contract a CPA with a physician, or several pharmacists who contract a CPA with several pharmacists), although a “primary prescriber” must be designated. The CPA must indicate the condition of the disease, the medications (or classes of medications) on which pharmacists are authorized to make decisions, and a procedure/protocol available for these decisions. Decisions must be reviewed at least every three months, at the same time as the agencies involved, and the protocols are only applicable for a maximum of two years.  The Alaska CPAs allow pharmacists to monitor drug treatment on 12 AAFC 52.995, which involves conducting a full medical experiment, measuring vital signs and ordering/evaluating laboratory tests covered by CPA.   CDTM is an extension of the traditional practice of pharmacists that allows for pharmacist-led management of drug-related problems (DOP), with an emphasis on a collaborative and interdisciplinary approach to pharmacy practice in the health sector. The conditions of a CPA are defined by the pharmacist and the cooperating physician, although models exist online. CPAs may be specific to a patient population of interest to both parties, a specific clinical situation or disease, and/or a factual protocol for managing the drug treatment of patients under CPA.
CPAs have been the subject of intensive debate in pharmacy and medicine. To participate in CPAs, pharmacists must be able to assess the health status of their patients, implement a pharmaceutical care plan, communicate with stakeholders and monitor patient progress. This also involves determining when it should intervene in a patient`s drug therapy.  Pharmacists may receive registration information from organizations approved by the Pharmacy Council.  Once authorized by the Board of Pharmacy, APh can conduct patient assessments, refer patients to providers, and work with other health care providers to manage patients` disease status by optimizing drug treatments.